Conditions: Hepatitis C
Keywords: Chronic Hepatitis C Protease Inhibitor Telaprevir
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: MP-424(H), PEG-IFN-a-2b, RBV intervention 2: MP-424 (L), PEG-IFN-a-2b, RBV
Intervention descriptions: intervention 1: MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks intervention 2: MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks

Protocol document: